SCHEMBL11943964

SCHEMBL11943964

O=c1c(OCC2CCCO2)c(N2CCN(S(=O)(=O)c3ccccn3)CC2)cnn1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 4/20 0.43
▸ DCTPP1 Q9H773 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ PKM P14618 1/20 0.37
▸ PKLR P30613 1/20 0.37
▸ POLB P06746 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945013 0.88 ALDH1A1 (0.56) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11943894 0.86 MAPT (0.46) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11945253 0.84 ALDH1A1 (0.46) MAPTALDH1A1DCTPP1KMT2ANPC1
SCHEMBL11943941 0.84 ALDH1A1 (0.46) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11944417 0.82 MAPT (0.49) MAPTALDH1A1DCTPP1KMT2ANPC1
SCHEMBL11945014 0.82 MAPT (0.45) MAPTALDH1A1DCTPP1KMT2AMEN1
SCHEMBL11945087 0.81 KDM4E (0.38) MAPTALDH1A1KMT2AMEN1CA12
SCHEMBL11945088 0.81 KDM4E (0.52) ALDH1A1KMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL11943984 0.80 ALDH1A1 (0.47) MAPTALDH1A1DCTPP1KMT2ANPC1
SCHEMBL11943971 0.80 GRM7 (0.38) MAPTALDH1A1KMT2AMEN1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback